drugset / Trial / NCT00698087
Comparison of Safety, Immuno- and Reactogenicity of MPL-Adjuvanted Recombinant Hepatitis B Vaccine to That of Engerix™-B
RandomizedParallel-groupTriple-blindPrevention
Summary
The purpose of the study is to compare the safety, reactogenicity and immunogenicity of different formulations of adjuvanted recombinant hepatitis B vaccine to that of Engerix™-B when administered at 0, 2 months with a booster at month 12 if necessary
Timeline
- Start
- 1995-01
- Primary completion
- 1996-02
- Completion
- 1996-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Engerix-B | Vaccine | — | Intramuscular |
| Subject | MPL-Adjuvanted Recombinant Hepatitis B Vaccine | Vaccine | — | Intramuscular |